Anteris Technologies develops structural heart devices, led by the DurAVR biomimetic transcatheter aortic valve designed to mimic native valve function. The system combines a single-piece tissue valve, ADAPT anti-calcification tissue processing, and a balloon-expandable delivery platform aimed at easier coronary access. The company is clinically focused on aortic valve disease and remains at a development and early commercialization stage relative to large heart-valve incumbents.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0.6 | — | -20.8 | — |
| Q3 2025 | 0.4 | — | -22.2 | — |
| Q4 2025 | 0.3 | — | -29.2 | — |
| Q1 2026 | 0.5 | — | -23 | — |
| Q2 2026 | 1 | 63.3% | -29.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Greene County Bancorp, Inc. (GCBC), Cantor Equity Partners IV, Inc. (CEPF), Limbach Holdings, Inc. (LMB), i3 Verticals, Inc. (IIIV), Ironwood Pharmaceuticals, Inc. (IRWD), Real REMAX Group Inc. (REAX)